• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Recent Advances in the Study of β-Heptaacetylrutinose (CAS: 5239-09-8): Synthesis, Applications, and Pharmacological Potential

In recent years, β-Heptaacetylrutinose (CAS: 5239-09-8) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, a fully acetylated derivative of rutinose, serves as a crucial intermediate in the synthesis of various glycosides and flavonoid conjugates. Recent studies have explored its role in enhancing drug bioavailability, modulating biological pathways, and serving as a scaffold for novel drug design. This research brief aims to synthesize the latest findings on β-Heptaacetylrutinose, highlighting its chemical synthesis, biological activities, and emerging applications in medicine.

The synthesis of β-Heptaacetylrutinose has been optimized through innovative chemical and enzymatic approaches. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a high-yield, regioselective acetylation method using rutinose as the starting material, achieving over 90% purity. The process leverages mild reaction conditions and eco-friendly catalysts, addressing previous challenges related to scalability and environmental impact. Furthermore, advancements in enzymatic acetylation have enabled the production of β-Heptaacetylrutinose with enhanced stereochemical control, which is critical for its application in chiral drug development.

Pharmacological investigations have revealed that β-Heptaacetylrutinose exhibits promising bioactivity profiles. In vitro studies indicate its potential as an anti-inflammatory agent, with demonstrated inhibition of key pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, its acetylated structure enhances membrane permeability, making it a valuable candidate for improving the delivery of poorly soluble drugs. Recent preclinical trials have explored its use in combination therapies for chronic inflammatory diseases, with preliminary results showing synergistic effects when co-administered with conventional therapeutics.

Beyond its therapeutic potential, β-Heptaacetylrutinose has found applications in nanotechnology and targeted drug delivery systems. Researchers have successfully conjugated this compound with nanoparticles to create hybrid carriers capable of site-specific drug release. A 2024 study in Advanced Drug Delivery Reviews highlighted its role in stabilizing lipid-based nanoparticles, thereby improving their circulatory half-life and reducing off-target effects. These innovations underscore the versatility of β-Heptaacetylrutinose in addressing contemporary challenges in drug formulation and delivery.

In conclusion, β-Heptaacetylrutinose (CAS: 5239-09-8) represents a multifaceted compound with broad implications for chemical biology and pharmaceutical sciences. Ongoing research continues to uncover its mechanistic underpinnings and expand its applications, from synthetic chemistry to clinical therapeutics. Future directions may include exploring its role in personalized medicine and further optimizing its synthetic pathways for industrial-scale production. As the field progresses, β-Heptaacetylrutinose is poised to play a pivotal role in the development of next-generation pharmaceuticals.

• 604-68-2([(2R,3R,4S,5R,6R)-3,4,5,6-tetrakis(acetyloxy)oxan-2-yl]methyl acetate)
• 22352-19-8(Octaacetyl-β-maltose)
• 4163-60-4([(2R,3S,4S,5R,6S)-3,4,5,6-tetrakis(acetyloxy)oxan-2-yl]methyl acetate)
• 5346-90-7(α-D-Cellobiose octaacetate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)